A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.

ABSTRACT:

SUBMITTER: Heß G 

PROVIDER: S-EPMC12819100 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature